Inolimomab
From Wikipedia, the free encyclopedia
Monoclonal antibody
Pharmaceutical compound
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | CD25 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
 N Y (what is this?) (verify) | |
Inolimomab is a mouse monoclonal antibody developed as an immunosuppressive drug against graft-versus-host disease. Its target is the alpha chain of the interleukin-2 receptor.[1][2]
- ↑ Piñana JL, Valcárcel D, Martino R, Moreno ME, Sureda A, Briones J, et al. (November 2006). "Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease". Biology of Blood and Marrow Transplantation. 12 (11): 1135–1141. doi:10.1016/j.bbmt.2006.06.010. PMID 17085306.
- ↑ Dartois C, Freyer G, Michallet M, Hénin E, You B, Darlavoix I, et al. (2007). "Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease". Clinical Pharmacokinetics. 46 (5): 417–432. doi:10.2165/00003088-200746050-00004. PMC 2760126. PMID 17465640.
| Intracellular (initiation) |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular (reception) |
| ||||||||||||||
| Extracellular |
| ||||||||||||||
| Unsorted |
| ||||||||||||||
| IL-1 |
| ||||
|---|---|---|---|---|---|
| IL-2 | |||||
| IL-3 | |||||
| IL-4 |
| ||||
| IL-5 |
| ||||
| IL-6 |
| ||||
| IL-7 |
| ||||
| IL-8 |
| ||||
| IL-9 |
| ||||
| IL-10 |
| ||||
| IL-11 |
| ||||
| IL-12 |
| ||||
| IL-13 |
| ||||
| IL-15 |
| ||||
| IL-17 |
| ||||
| IL-18 |
| ||||
| IL-20 |
| ||||
| IL-21 |
| ||||
| IL-22 |
| ||||
| IL-23 |
| ||||
| IL-27 |
| ||||
| IL-28 | |||||
| IL-31 |
| ||||
| IL1RL1 |
| ||||
| IL1RL2 |
| ||||
| Others |
| ||||
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |